Phase 2 Data: Rigosertib (Traws Pharma) Shows 80% Response Rate in RDEB SCC
Rigosertib (Traws Pharma) is showing promise in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated cutaneous squamous cell carcinoma (RDEB SCC), according to a study in the British Journal of Dermatology.